KRAS and neoplasm: A miR-34a-expressing DNA vector encapsulated in liposomal nanoparticles (nanovector) is effective at reducing tumor growth in subcutaneous and orthotopic xenograft models, and more so than similar nanovector strategy with KRAS-targeting miR-143 and miR-145 [130].